Your session is about to expire
← Back to Search
MRX-2843 for Leukemia
Study Summary
This trial is testing a new drug for people with leukemia who haven't responded to other treatments. The drug will be given in increasing doses to see what effect it has.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken any experimental drugs or kinase inhibitors in the last 28 days or longer.I have an ongoing infection that isn't under control.I haven't had systemic treatment for other cancers in the last 2 years, except for certain skin or cervical conditions.My kidney function, measured by creatinine clearance, is good.I have Type 1 Diabetes or am at high risk for it.I have had radionuclide treatment within the last 6 weeks.I can care for myself but may not be able to do active work.I have FLT3ITD+ and was treated with a FLT3 inhibitor before.I weigh at least 40 Kg.My leukemia diagnosis is confirmed and it has not responded to at least one treatment.My white blood cell count is below 25,000/mm3, or I am taking hydroxyurea to lower it for the study.I am willing and able to follow the study rules and work with the research team.My heart function is good despite past severe heart failure.I have active and serious graft-versus-host disease.I have been diagnosed with active hepatitis B or C.I don't have any health issues that could affect how a drug works in my body.I haven't had cancer treatment in the last 14 days, except possibly hydroxyurea.I am not pregnant or breastfeeding and have negative pregnancy tests.I can take pills by mouth.I still have side effects from previous treatments, except for hair loss.I am at least 12 years old.I had major surgery less than 4 weeks ago.I have active leukemia in my brain or spinal cord.I agree to use two forms of birth control or remain abstinent.I need blood thinners or antiplatelet drugs for my condition.I have taken calcineurin inhibitors within the last month.I have been diagnosed with acute promyelocytic leukemia.I have or suspect I have retinitis pigmentosa, or it runs in my family.
- Group 1: Dose Escalation - Level 4
- Group 2: Dose Escalation - Level 5
- Group 3: Expansion Arm at RP2D
- Group 4: Dose Escalation - Level 1
- Group 5: Dose Escalation - Level 3
- Group 6: Dose Escalation - Level 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the enrollment window for this study still open?
"This clinical trial is actively recruiting participants, as indicated by its listing on the clinicaltrials.gov site. The posting date of April 1st 2022 and most recent update from July 6th are also noted there."
Has the FDA given its blessing for MRX-2843 to be utilized in medical treatments?
"MRX-2843 received the lowest safety rating, 1 out of 3, as this is a Phase 1 trial. This indicates that there is only minimal data so far in terms of efficacy and safety."
What is the ceiling of participants for this research endeavor?
"Affirmative. The information on clinicaltrials.gov suggests that this medical trial is actively recruiting patients - it was initially posted on April 1st 2022 and last updated on July 6th 2022. Approximately 50 individuals must be sourced from 3 distinct sites for the study to reach completion."
Share this study with friends
Copy Link
Messenger